{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/lipid-modification-cvd-prevention/","result":{"data":{"firstChapter":{"id":"7834a360-a716-55db-beef-e74397381f6b","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 133d749a-7b51-492e-af9a-a78a469fc229 --><h1>Lipid modification - CVD prevention: Summary</h1><!-- end field 133d749a-7b51-492e-af9a-a78a469fc229 -->","htmlStringContent":"<!-- begin item 4f3aa19b-67a7-4146-8ff4-119ea3e400f7 --><!-- begin field 808ba09e-6f06-4183-bcd0-3cdd35ee98b7 --><ul><li>Cardiovascular disease (CVD) is an umbrella term which describes a range of conditions that affect the heart, the blood vessels, or both. </li><li>The risk of CVD can be reduced by modification of the blood lipid profile.</li><li>CVD is caused by blood clots (thrombosis), or atherosclerosis.</li><li>Atherosclerosis is a condition where there is a build-up of fatty deposits (plaques) inside an artery which cause the artery to harden and narrow, restricting blood flow.</li><li>Cardiovascular conditions caused by atherosclerosis include: </li><li style=\"list-style-type: none;\"><ul><li>Coronary heart disease (including angina and myocardial infarction).</li><li>Stroke.</li><li>Transient ischaemic attack (TIA).</li><li>Peripheral arterial disease.</li></ul></li><li>Modification of the blood lipid profile can reduce CVD risk.<ul><li>Total cholesterol is an important predictor of CVD events. However, non-high density lipoprotein cholesterol (non-HDL-C) — the difference between total and HDL-C is a powerful risk factor.</li><li>Non-HDL-C has replaced low-density lipoprotein cholesterol (LDL-C) as the primary target for reducing cardiovascular risk with lipid-modifying treatment.</li><li>A raised triglyceride level is a risk factor for CVD and is independent of total cholesterol.</li></ul></li><li>For primary prevention of CVD, high-intensity statin treatment (atorvastatin 20 mg daily) should be offered to people:<ul><li>Aged 84 years and younger if their estimated 10-year risk of developing CVD using the QRISK assessment tool is 10% or more.</li><li>With type 1 diabetes (without the need for a formal risk assessment) who are aged more than 40 years, have had diabetes for more than 10 years or have established nephropathy, or have other CVD risk factors.</li><li>With chronic kidney disease, or familial hypercholesterolaemia (without the need for a formal risk assessment).</li></ul></li><li>For primary prevention of CVD, high-intensity statin treatment (atorvastatin 20 mg daily) should be considered in people (without the need for a formal risk assessment):<ul><li>With type 1 diabetes. </li><li>Aged 85 years of age or older, taking into account the benefits and risks of treatment and any comorbidities that make treatment appropriate.</li></ul></li><li>For secondary prevention of CVD, high-intensity statin treatment (atorvastatin 80 mg daily) should be advised in people with existing CVD (for example past or current history of myocardial infarction, angina, stroke, transient ischaemic attack, or peripheral arterial disease).</li><li>The decision to start statin treatment should be made after an informed discussion with the person about the risks and benefits of treatment, taking into account factors such as co-morbidities, potential benefits from lifestyle intervention, and the person's preference.</li><li>The aim of treatment is to achieve a greater than 40% reduction in non-HDL-C levels.</li><li>Before starting lipid modification therapy, the following baseline blood tests should be performed:<ul><li>A non-fasting lipid profile.</li><li>Liver function tests (transaminases).</li><li>Renal function, including estimated glomerular filtration rate.</li><li>HbA1c.</li><li>Creatine kinase (if the person has persistent generalized unexplained muscle pain).</li><li>Thyroid stimulating hormone, if dyslipidaemia is present.</li></ul></li><li>For primary and secondary prevention of CVD, management should involve:<ul><li>Addressing other modifiable CVD risk factors, such as smoking and obesity.</li><li>Identifying and managing secondary causes of dyslipidaemia.</li><li>Arranging follow-up to monitor for adverse effects and to review drug treatment.</li></ul></li></ul><!-- end field 808ba09e-6f06-4183-bcd0-3cdd35ee98b7 --><!-- end item 4f3aa19b-67a7-4146-8ff4-119ea3e400f7 -->","topic":{"id":"5303951d-71d9-506d-84ec-cbdd7ff3b93e","topicId":"dc4f1ad8-1fac-4248-9071-a622ca58dd2c","topicName":"Lipid modification - CVD prevention","slug":"lipid-modification-cvd-prevention","aliases":["CVD prevention - lipid modification"],"chapters":[{"id":"7834a360-a716-55db-beef-e74397381f6b","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"4149ed5c-ad54-5793-8860-4b2f82d94427","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"184e9f02-cec5-5813-a428-f3b70683deda","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"0fd087eb-ba58-59e6-b641-2161dd021687","slug":"changes","fullItemName":"Changes"},{"id":"6e535866-055b-5f94-8d43-67cc6c3262a6","slug":"update","fullItemName":"Update"}]},{"id":"6952071a-0b87-50ea-af6b-c7589b86f9bd","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"3de1ddbe-7a0f-5384-9939-9a56d2251dfc","slug":"goals","fullItemName":"Goals"},{"id":"1a8df6be-f747-5d74-81cf-54d938d5944b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80c40530-2e39-55a1-910d-b5226d83d67a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e9906a94-72bf-5a9e-8e05-bb7b6841fec3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"507f0f33-704f-5b79-813e-0ba2a367617e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c55b24f4-39a4-5919-8e05-5afc7b1ae5c6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f02326a5-5f6d-5026-9c8c-745fd760df23","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"f4e4cb23-7f1d-5543-a7a5-9316a25c589b","slug":"lipids-cardiovascular-health","fullItemName":"Lipids and cardiovascular health"}]},{"id":"5123c607-afa6-5c07-a939-547efe27b94c","slug":"management","fullItemName":"Management","subChapters":[{"id":"ec817edb-2375-548c-beb5-8afb1596d294","slug":"lipid-therapy-primary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - primary prevention of CVD"},{"id":"4cd90098-cba6-5b78-994c-9fc173b4fb3f","slug":"lipid-therapy-secondary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - secondary prevention of CVD"}]},{"id":"35a2dc51-a5b3-56bd-9a02-c420e08c1d0d","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"3e6af82a-f8f1-5d90-a988-05136fa101f3","slug":"statins","fullItemName":"Statins"}]},{"id":"238b503e-9352-5458-b356-3f6b521ef218","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"2dbe7113-fbe3-5fd2-bca1-2846dd9a39c8","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"fbe34d96-9294-5a30-8de1-1bc1f631ce69","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"df527078-d479-5b6f-aff8-247af2cdd323","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1a8284ce-a2e5-59db-9d07-596f590c3ec3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9fe03c85-09a6-5232-8343-e77d91ad6145","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d5bce13d-7bb2-5366-8bcc-28f538824ee4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f5e3b9df-860b-5c62-a358-a408038abc28","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"5303951d-71d9-506d-84ec-cbdd7ff3b93e","topicId":"dc4f1ad8-1fac-4248-9071-a622ca58dd2c","topicName":"Lipid modification - CVD prevention","slug":"lipid-modification-cvd-prevention","aliases":["CVD prevention - lipid modification"],"topicSummary":"Cardiovascular disease (CVD) is an umbrella term for diseases that involve the heart, blood vessels, or both, caused by atherosclerosis","lastRevised":"Last revised in October 2020","nextPlannedReviewBy":"2024-08-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2024-07","nextPlannedReviewByDisplay":"July 2024","specialities":[{"id":"fe645ae3-9536-5dfb-8c84-285b62195550","name":"Cardiovascular","slug":"cardiovascular"},{"id":"aa304738-44fc-5b1d-af3b-42cce5d27663","name":"Endocrine and metabolic","slug":"endocrine-metabolic"},{"id":"2454765b-1b2d-53fc-b288-17b66486f41a","name":"Preventative medicine","slug":"preventative-medicine"}],"chapters":[{"id":"7834a360-a716-55db-beef-e74397381f6b","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"4149ed5c-ad54-5793-8860-4b2f82d94427","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"184e9f02-cec5-5813-a428-f3b70683deda","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"0fd087eb-ba58-59e6-b641-2161dd021687","slug":"changes","fullItemName":"Changes"},{"id":"6e535866-055b-5f94-8d43-67cc6c3262a6","slug":"update","fullItemName":"Update"}]},{"id":"6952071a-0b87-50ea-af6b-c7589b86f9bd","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"3de1ddbe-7a0f-5384-9939-9a56d2251dfc","slug":"goals","fullItemName":"Goals"},{"id":"1a8df6be-f747-5d74-81cf-54d938d5944b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80c40530-2e39-55a1-910d-b5226d83d67a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e9906a94-72bf-5a9e-8e05-bb7b6841fec3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"507f0f33-704f-5b79-813e-0ba2a367617e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c55b24f4-39a4-5919-8e05-5afc7b1ae5c6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f02326a5-5f6d-5026-9c8c-745fd760df23","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"f4e4cb23-7f1d-5543-a7a5-9316a25c589b","slug":"lipids-cardiovascular-health","fullItemName":"Lipids and cardiovascular health"}]},{"id":"5123c607-afa6-5c07-a939-547efe27b94c","slug":"management","fullItemName":"Management","subChapters":[{"id":"ec817edb-2375-548c-beb5-8afb1596d294","slug":"lipid-therapy-primary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - primary prevention of CVD"},{"id":"4cd90098-cba6-5b78-994c-9fc173b4fb3f","slug":"lipid-therapy-secondary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - secondary prevention of CVD"}]},{"id":"35a2dc51-a5b3-56bd-9a02-c420e08c1d0d","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"3e6af82a-f8f1-5d90-a988-05136fa101f3","slug":"statins","fullItemName":"Statins"}]},{"id":"238b503e-9352-5458-b356-3f6b521ef218","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"2dbe7113-fbe3-5fd2-bca1-2846dd9a39c8","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"fbe34d96-9294-5a30-8de1-1bc1f631ce69","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"df527078-d479-5b6f-aff8-247af2cdd323","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1a8284ce-a2e5-59db-9d07-596f590c3ec3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9fe03c85-09a6-5232-8343-e77d91ad6145","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d5bce13d-7bb2-5366-8bcc-28f538824ee4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f5e3b9df-860b-5c62-a358-a408038abc28","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"5303951d-71d9-506d-84ec-cbdd7ff3b93e"}},"staticQueryHashes":["3666801979"]}